# A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

Source: https://onco.cc/trials/nct07566052/  
OnCo record `nct07566052` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Setidegrasib in non-small-cell lung cancer, now recruiting.

## Summary

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation is a phase 3 interventional study registered as NCT07566052, led by Astellas Pharma Global Development, and recruiting on the registry. Official title: A Randomised, Open-label, Phase 3 Study of Setidegrasib (ASP3082) Versus Docetaxel in Participants With KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (CPI). Planned enrolment is 356 participants (estimated). The study started in 2026-04-28 and primary completion is expected in 2030-06-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT07566052
- Phase: 3
- Setting: A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) Versus Docetaxel in Participants With KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum Based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)
- Sponsor: Astellas Pharma Global Development
- Enrolled: 356

## Sources

- ClinicalTrials.gov NCT07566052: https://clinicaltrials.gov/study/NCT07566052

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Setidegrasib](https://onco.cc/drugs/setidegrasib/)
- companies: [Astellas](https://onco.cc/companies/astellas/)

---
JSON: https://onco.cc/api/v1/entities/nct07566052.json